Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05588713
Other study ID # 467830400
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 1, 2023
Est. completion date June 2025

Study information

Verified date May 2023
Source Uppsala University
Contact Matilda Frick, PhD
Phone +46736942728
Email matilda.frick@neuro.uu.se
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

ADHD is one of the most prevalent psychiatric conditions, consuming a large proportion of resources in psychiatric care, often accompanied by long waiting lists to receive proper assessment. The number of ADHD cases has increased, possible due to heightened awareness of the condition. There are large prevalence differences, potentially due to variations in assessments procedures. Many clinicians and parents view the diagnostic process as too extensive, taking time from treatment and interventions. In addition, assessments may be perceived as too focused on diagnostic criteria to be fully helpful. Systematic research on how assessment procedures can be optimized is essentially lacking. It is largely unknown whether brief protocols including medical history, diagnostic interview, and rating scales differ from comprehensive protocols that also encompass neuropsychological testing regarding validity, reliability, patient satisfaction and cost-effectiveness. Further, feasible biomarkers (e.g. heart rate variability, pupil dilation and the pupillary light reflex) of the autonomic nervous system have been proposed as indicators of diagnostic status. The aim of this study is to gain knowledge about diagnostic processes to enable valid, reliable, and cost-effective ADHD assessments. Using a randomized controlled trial design (N = 240 children, 8-17 years, referred to child and adolescent psychiatric units), differences between a brief and a comprehensive ADHD assessment protocol regarding assessment outcome, reliability, validity, patient satisfaction, and future outcome taking gender into account will be examined. The investigators will explore diagnostic sensitivity and specificity of the included assessment instruments and estimate cost-effectiveness of the brief and comprehensive protocols to enable policy makers to make informed decisions. The project will provide important knowledge for patients and clinicians, and inform our understanding of mechanisms underpinning ADHD.


Recruitment information / eligibility

Status Recruiting
Enrollment 240
Est. completion date June 2025
Est. primary completion date June 2025
Accepts healthy volunteers No
Gender All
Age group 8 Years to 17 Years
Eligibility Inclusion Criteria: - Age 8-17 years - Referral for ADHD assessment Exclusion Criteria: - Suspected intellectual disability - Substance abuse - Psychosis - Severe depression - Parent not fluent in Swedish - Child not living with legal guardian - Child having protected identity

Study Design


Related Conditions & MeSH terms

  • Attention Deficit Disorder with Hyperactivity
  • Attention Deficit Hyperactivity Disorder
  • Hyperkinesis

Intervention

Procedure:
Brief assessment protocol
The intervention constitutes of a brief assessment protocol for assessing ADHD.
Comprehensive assessment protocol
The intervention constitutes of a comprehensive assessment protocol for assessing ADHD.

Locations

Country Name City State
Sweden Child and adolescent psychiatry unit Uppsala

Sponsors (2)

Lead Sponsor Collaborator
Uppsala University Swedish Council for Working Life and Social Research

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Difference in assessment duration between the two protocols Numbers of initiated hours to complete the assessments Immediately after completion of assessment
Primary Difference in prevalence of assigned diagnoses between the two protocols Proportion of ADHD diagnoses (including presentation) and comorbid diagnoses Immediately after completion of assessment
Primary Difference in assessor certainty between the two protocols The certainty score will be assigned by the assessor on a 1 to 10-point scale, where 6 to 10 index the assessor's degree of certainty of the child meeting criteria for ADHD and 1 to 5 the assessor's certainty of the child not meeting criteria for ADHD Immediately after completion of assessment
Primary Difference in reliability between the two protocols A second assessor will review the assessment material (blind to diagnostic status) and assign diagnostic status to each case. S/he will be given all information included in the assessment, except for diagnostic status and asked to assign diagnosis/es as well as a certainty score on a 1 to 10-point scale, where 6 to 10 index the assessor's degree of certainty of the child meeting criteria for ADHD and 1 to 5 the assessor's certainty of the child not meeting criteria for ADHD. Immediately after completion of assessment
Primary Difference in validity between the two protocols An experienced clinician will assign diagnostic status using Longitudinal Expert All Data (LEAD; i.e. review of all available material) roughly one year post assessment, after follow-up data has been collected. For this purpose, all available material will include information included in the assessment, medical records following the assessment, and symptom ratings at follow up. S/he will assign diagnosis/es and a certainty score (on a 1 to 10-point scale, where 6 to 10 index the assessor's degree of certainty of the child meeting criteria for ADHD and 1 to 5 the assessor's certainty of the child not meeting criteria for ADHD), blind to original diagnostic status. 1 year after completion of assessment
Primary Difference in patient satisfaction between the two protocols Children (> 13 years) and all legal guardians will rate satisfaction with the assessment process right after the assessment, using a satisfaction scale ranging from 1 to 5, where 5 indicates high satisfaction with the assessment. Immediately after completion of assessment
Primary Difference in patient satisfaction between the two protocols at follow-up Children (> 13 years) and all legal guardians will rate satisfaction with the assessment process at follow up, using a satisfaction scale ranging from 1 to 5, where 5 indicates high satisfaction with the assessment. 1 year after completion of assessment
Primary Difference in cost effectiveness between the two protocols To enable cost-effectiveness analyses, a health economist will build a model based on the following: Child (> 13 years) and parent ratings of child quality of life at baseline and follow-up using the Child Health Utility D9 (CHUD-9), on a scale from 1 to 5, where 1 indicates high quality of life. CHUD-9 will be used to estimate quality adjusted life years (QALYs). Personnel resources and overheads will be estimated for each protocol, and other inputs (such as risks of negative school outcomes and related costs, as well as costs related to ADHD treatment) will be collected from the literature. Consumption of healthcare and school resources for children, as well as productivity losses associated with absenteeism and presentism at school will be estimated from the Treatment Inventory of Costs in Patients (TIC-P), which will be filled out by the caregivers and teachers. 1 year after completion of assessment
Secondary Sensitivity and specificity of the diagnostic interview in relation to ADHD diagnosis Discriminative validity (positive predictive value, sensitivity, specificity, and area under the curve) will be calculated for the diagnostic interview, Mini Internationell Neuropsykiatrisk Intervju (MINI-kid), using formal diagnosis as the external criterion. At baseline
Secondary Sensitivity and specificity of the ADHD-symptom rating scale in relation to ADHD diagnosis Discriminative validity (positive predictive value, sensitivity, specificity, and area under the curve) will be calculated for the Adult ADHD Self-Report Scale Adolescent version (ASRS-A), in which symptoms are rated on a scale from 1-5, where 5 indicate high symptoms, with formal diagnosis as the external criterion. At baseline
Secondary Sensitivity and specificity of workning memory in relation to ADHD diagnosis Discriminative validity (positive predictive value, sensitivity, specificity, and area under the curve) will be calculated for the working memory index from Wechlser Intelligence Scale for Children (WISC-V), on a scale from 1 to 19, where 19 indicated high ability for workning memory. Formal diagnosis will be used as the external criterion. At baseline
Secondary Sensitivity and specificity of Continous Performance Test in relation to ADHD diagnosis Discriminative validity (positive predictive value, sensitivity, specificity, and area under the curve) will be calculated for the Conners Continous Performance Test (CPT-3). The CPT-3 renders a T-score ranging from 0-100, where 50 is the mean and 15 the standard diviation. Higher scores indicate better attention abilities. Formal diagnosis will be used as the external criterion. At baseline
Secondary Sensitivity and specificity of heart rate variability in relation to ADHD diagnosis Discriminative validity (positive predictive value, sensitivity, specificity, and area under the curve) will be calculated for heart rate variability assessed during the Conners Continous Performance Test (CPT-3). Formal diagnosis will be used as the external criterion. At baseline
Secondary Sensitivity and specificity of pupil dilation in relation to ADHD diagnosis Discriminative validity (positive predictive value, sensitivity, specificity, and area under the curve) will be calculated for pupil dilation assessed with an eye-tracker during the Conners Continous Performance Test (CPT-3). Formal diagnosis will be used as the external criterion. At baseline
Secondary Sensitivity and specificity of the pupillary light reflex in relation to ADHD diagnosis Discriminative validity (positive predictive value, sensitivity, specificity, and area under the curve) will be calculated for the pupillary light reflex. Formal diagnosis will be used as the external criterion. At baseline
See also
  Status Clinical Trial Phase
Recruiting NCT06129396 - Effects of Aerobic Exercise Intervention in Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD) N/A
Completed NCT04779333 - Lifestyle Enhancement for ADHD Program 2 N/A
Recruiting NCT05935722 - Evaluation of a Home-based Parenting Support Program: Parenting Young Children N/A
Completed NCT03148782 - Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase N/A
Completed NCT04832737 - Strength-based Treatment Approach for Adults With ADHD N/A
Recruiting NCT04631042 - Developing Brain, Impulsivity and Compulsivity
Recruiting NCT05048043 - Development of a Game-supported Intervention N/A
Completed NCT03337646 - Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism Phase 4
Not yet recruiting NCT06454604 - Virtual Reality Treatment for Emerging Adults With ADHD Phase 2
Not yet recruiting NCT06406309 - Settling Down for Sleep in ADHD: The Impact of Sensory and Arousal Systems on Sleep in ADHD N/A
Not yet recruiting NCT06080373 - Formulation-based CBT for Adult Inmates With ADHD: A Randomized Controlled Trial N/A
Completed NCT02911194 - a2 Milk for Autism and Attention-deficit Hyperactivity Disorder (ADHD) N/A
Completed NCT02477280 - Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance Phase 4
Completed NCT02555150 - A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD Phase 3
Completed NCT02390791 - New Technologies to Help Manage ADHD N/A
Completed NCT02780102 - Cognitive-Motor Rehabilitation, Stimulant Drugs, and Active Control in the Treatment of ADHD N/A
Completed NCT02473185 - Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance During the QbTest Phase 4
Completed NCT02829970 - Helping College Students With ADHD Lead Healthier Lifestyles N/A
Recruiting NCT04296604 - Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations N/A
Recruiting NCT04175028 - Neuromodulation of Executive Function in the ADHD Brain N/A